Daily Stock Analysis, BIIB, Biogen Inc, priceseries

Biogen Inc. Daily Stock Analysis
Stock Information
Open
287.75
Close
284.75
High
288.11
Low
283.36
Previous Close
287.63
Daily Price Gain
-2.88
YTD High
301.42
YTD High Date
Jan 10, 2017
YTD Low
260.50
YTD Low Date
Feb 2, 2017
YTD Price Change
-6.96
YTD Gain
-2.39%
52 Week High
333.65
52 Week High Date
Aug 2, 2016
52 Week Low
223.02
52 Week Low Date
Jun 27, 2016
52 Week Price Change
27.53
52 Week Gain
10.70%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jul 14. 2016
252.87
Aug 24. 2016
310.44
29 Trading Days
22.77%
Link
Company Information
Stock Symbol
BIIB
Exchange
NasdaqGS
Company URL
http://www.biogen.com
Company Phone
7814642000
CEO
George A. Scangos
Headquarters
Massachusetts
Business Address
225 BINNEY STREET, CAMBRIDGE, MA 02142
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000875045
About

Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurodegenerative diseases, hematologic conditions, and autoimmune disorders.

Description

Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurodegenerative diseases, hematologic conditions, and autoimmune disorders. It offers TECFIDERA, AVONEX, and PLEGRIDY to treat relapsing forms of multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn's disease; and FAMPYRA to improve walking ability for patients with MS. The company also provides ELOCTATE to treat adults and children with hemophilia A for control of bleeding episodes; ALPROLIX to treat adults and children with hemophilia B for control of bleeding episodes; RITUXAN for treating non-Hodgkin's lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), as well as two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with previously untreated CLL; and FUMADERM to treat plaque psoriasis. The company's products in Phase III development stage comprise ZINBRYTA, a monoclonal antibody for the treatment of relapsing-remitting MS; Aducanumab for Alzheimer's disease; and ISIS-SMNRx for spinal muscular atrophy. Its Phase II clinical trial products include Anti-LINGO for optic neuritis and MS; Amiselimod for multiple autoimmune indications; BAN2401 and E2609 for Alzheimer's disease; Raxatrigine for trigeminal neuralgia; rAAV-XLRS for X-linked juvenile retinoschisis; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I clinical trial products comprise Dapirolizumab pegol for systemic lupus erythematosus (SLE); ISIS – DMPK for myotonic dystrophy; Anti-BDCA2 for SLE; Anti-alpha-synuclein for Parkinson's disease; and BIIB063 for sjogren's syndrome. The company has a strategic research collaboration with Ionis Pharmaceuticals, Inc. It offers products primarily through its own sales force, marketing groups, and third parties worldwide. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.